Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

Disease Types: Lung, Melanoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment 

For more information:

https://clinicaltrials.gov/ct2/show/NCT04609566?cond=A+phase+2+study+of+brentuximab+vedotin+in+combination+with+pembrolizumab+in+subjects+with+metastatic+solid+malignancies+after+progression+on+prior+PD-1+inhibitor+treatment&draw=2&rank=1